Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-196-2 | CAS number: 79-33-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
The genotoxicity of L(+) lactic acid was assessed in a weight of evidence approach. L(+) lactic acid was tested negative in a bacterial reverse gene mutation test conducted according to OECD 471, in an in vitro chromosome aberration assay conducted according to OECD 473 and in a mammalian cell gene mutation assay conducted according to OECD 476 (nowadays OECD 490). Based on results, the test item was considered to not induce genetic toxicity.
Link to relevant study records
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2014-01-23 to 2014-05-22
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- adopted 21 July 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- 31 May 2008
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): L(+)-lactic acid
- Analytical purity: 90%
- Lot/batch No.: 1208002033
- Expiration date of the lot/batch: 2015-01-01
- Storage condition of test material: room temperature in the dark - Target gene:
- n.a.
- Species / strain / cell type:
- lymphocytes: peripheral human lymphocytes
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells:
Blood was collected from healthy adult, non-smoking, male volunteers. Blood samples were collected by venipuncture using the Venoject multiple sample blood collecting system with a suitable size sterile vessel containing sodium heparin (Vacuette, Greiner Bio-One, Alphen aan den Rijn, The Netherlands). Immediately after blood collection lymphocyte cultures were started.
- Suitability of cells:
Peripheral human lymphocytes are recommended in international guidelines (e.g. OECD and EC).
MEDIA USED
- Type and identity of media:
- Culture medium: Culture medium consisted of RPMI 1640 medium (Invitrogen Corporation), supplemented with 20% (v/v) heat-inactivated (56 °C; 30 min) foetal calf serum (Invitrogen Corporation), L-glutamine (2 mM) (Invitrogen Corporation), penicillin/streptomycin (50 U/ml and 50 μg/ml respectively) (Invitrogen Corporation) and 30 U/ml heparin (Sigma, Zwijndrecht, The Netherlands).
- Lymphocyte cultures: Whole blood (0.4 mL) treated with heparin was added to 5 mL or 4.8 mL culture medium (in the absence and presence of S9-mix, respectively). Per culture 0.1 mL (9 mg/mL) phytohaemagglutinin (Remel, Europe Ltd., United Kingdom) was added. - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix
- Test concentrations with justification for top dose:
- Dose range finding assay:
A concentration of 901 µg/mL showed no precipitation in the culture medium. Therefore, this concentration was used as the highest concentration in the dose range finding test.
With and without S9: 10, 33, 100, 333, 901 µg/mL (equal to concentrations of 0.1, 0.4, 1.1, 3.7 and 10 mM)
First cytogenetic assay:
Based on the results of the dose range finding test the following dose levels were selected for the cytogenetic assay:
With and without S9: 10, 100, 901 µg/mL (equal to concentrations of 0.1, 1.1 and 10 mM)
Second cytogenetic assay:
Without S9: 100, 333, 666, 901 µg/mL (equal to concentrations of 1.1, 3.7, 7.4 and 10 mM)
With S9: 10, 100, 901 µg/mL (equal to concentrations of 0.1, 1.1 and 10 mM) - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: RPMI 1640 medium
- Untreated negative controls:
- yes
- Remarks:
- solvent
- Negative solvent / vehicle controls:
- yes
- Remarks:
- solvent: RPMI 1640
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- 0.5 and 0.75 μg/mL for a 3 h exposure period, 0.2 and 0.3 μg/mL for a 24 h exposure period and 0.1 and 0.15 μg/mL for a 48 h exposure period. Solvent for positive controls: Hank´s Balanced Salt Solution (HBSS)
- Untreated negative controls:
- yes
- Remarks:
- solvent
- Negative solvent / vehicle controls:
- yes
- Remarks:
- solvent: RPMI 1640
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- 10 μg/mL for a 3 h exposure period (24 h fixation time). Solvent for positive controls: Hank's Balanced Salt Solution (HBSS)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Preincubation period: 48 ± 2 hours
- Exposure duration: experiment 1: 3 hours (with and without metabolic activation); experiment 2: 24 and 48 hours without metabolic activation and 3 hours with metabolic activation
- Expression time (cells in growth medium): experiment 1: 20 to 22 hours; experiment 2: 44 to 46 hours
- Fixation time (start of exposure up to fixation or harvest of cells): experiment 1: 24 hours; experiment 2: 48 hours
SPINDLE INHIBITOR (cytogenetic assays): colchicine 0.5 µg/mL medium during the last 2.5 to 3 hours of the culture period
STAIN (for cytogenetic assays): 5% (v/v) Giemsa for 10 to 30 minutes
NUMBER OF CELLS EVALUATED: 100 per culture
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index from at least 1000 cells - Evaluation criteria:
- A test substance was considered positive (clastogenic) in the chromosome aberration test if:
a) It induced a dose-related statistically significant (Chi-square test, one-sided, p< 0.05) increase in the number of cells with chromosome aberrations.
b) A statistically significant and biologically relevant increase in the frequencies of the number of cells with chromosome aberrations was observed in the absence of a clear dose-response relationship.
A test substance was considered negative (not clastogenic) in the chromosome aberration test if:
None of the tested concentrations induced a statistically significant (Chi-square test, one-sided, p< 0.05) increase in the number of cells with chromosome aberrations.
The preceding criteria are not absolute and other modifying factors might enter into the final evaluation decision. - Statistics:
- The incidence of aberrant cells (cells with one or more chromosome aberrations, gaps included or excluded) for each exposure group outside the laboratory historical control data range was compared to that of the solvent control using Chi-square statistics:
(N-1) (ad-bc)^2
X^2 = ------------------------
(a+b) (c+d) (a+c) (b+d)
Where:
a = the total number of aberrant cells in treated cultures to be compared with the control.
b = the total number of aberrant cells in the control cultures.
c = the total number of non aberrant cells in treated cultures to be compared with the control.
d = the total number of non aberrant cells in the control cultures.
N = sum of n0 and n1.
n0 = the total number of cells scored in the control cultures.
n1 = the total number of cells scored in the treated cultures.
(N-1) (ad-bc)^2
If P X^2 > ----------------------------- (one-tailed) is small (p< 0.05) the hypothesis that the
(a+b) (c+d) (a+c) (b+d)
incidence of cells with chromosome aberrations is the same for both the treated and the solvent control group is rejected and the number of aberrant cells in the test group is considered to be significantly different from the control group at the 95 % confidence level. - Key result
- Species / strain:
- lymphocytes: peripheral human lymphocytes
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- based on determination of the mitotic index.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: At the highest concentration of the test substance (10 mM equal to 901 µg/mL) the pH was 7.1 compared to a pH of 7.8 in the solvent control.
- Effects of osmolality: At the highest concentration of the test substance (10 mM equal to 901 µg/mL) the osmolarity was 275 mOsm/kg compared to an osmolarity of 269 mOsm/kg in the solvent control.
- Water solubility: miscible
- Precipitation: No
RANGE-FINDING/SCREENING STUDIES: In the dose range finding test blood cultures were treated with 10, 33, 100, 333, 901 µg/mL L(+)-lactic acid/mL culture medium (equal to concentrations of 0.1, 0.4, 1.1, 3.7 and 10 mM) with and without S9-mix.
COMPARISON WITH HISTORICAL CONTROL DATA: The number of cells with chromosome aberrations found in the solvent control cultures was within the laboratory historical control data range.
For individual results see box 'Any other information on results incl. tables'. - Conclusions:
- L(+)-lactic acid is considered to be not clastogenic in the in vitro mammalian chromosomal aberration test using human lymphocytes, with and without metabolic activation.
- Executive summary:
In an in vitro cytogenicity assay conducted according to OECD guideline 473, peripheral human lymphocyte cultures were exposed to L(+)-lactic acid (90% purity), solved in RPMI 1640 cell culture medium. In the first experiment, the doses were 0, 10, 100, 901 µg/mL with and without metabolic activation. In the second experiment doses were 0, 100, 333, 666, 901 µg/mL without metabolic activation and 0, 10, 100, 901 µg/mL with metabolic activation (rat liver S9-mix).
L(+)-lactic acid was tested up to 901 µg/mL, which was cytotoxic based on determination of the mitotic index after an exposure time of 24 and 48 hours. The percentage of the mitotic index after 24 hours of 901 µg/mL was 55%, that after 48 hours of 901 µg/mL 49%. Concentrations lower than 901 µg/mL did not cause a dose-dependent decrease in the percentage of the mitotic index after 24 and 48 hours of exposure. The mitotic index after 3 hours of exposure was lower compared to control (66% in experiment 1, 84% in experiment 2) but did not reach the threshold value of 45 ± 5% according to OECD guideline 473 for cytotoxicity. Positive controls induced the appropriate responses. There was no evidence for a concentration related positive response of chromosome aberration induced over background.
This study is classified as acceptable and satisfies the requirement for the in vitro mammalian chromosomal aberration test according to OECD 473.
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2014-01-17 to 2014-05-13
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- adopted 21 July 1997
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- - Name: L(+)-lactic acid
- CAS No.: 79-33-4
- Appearance: clear colourless liquid
- Batch No.: 1208002033
- Purity: 90%
- Storage: at room temperature in the dark
- Expiry date: 2015-01-01
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: L(+)-lactic acid was dissolved in Milli-Q water (Millipore Corp., Bedford, MA., USA). Preparation of test solutions started with solutions of 50 mg/mL applying vortexing resulting in a clear colourless solution.
The lower test concentrations were prepared by subsequent dilutions in Milli-Q water. The stock solution was filter (0.22 μm)-sterilized. Test substance concentrations were used within 2 hours after preparation. - Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: Trinova Biochem GmbH, Germany (Master culture from Dr. Bruce N. Ames) - Additional strain / cell type characteristics:
- other: each strain contained the following additional mutations: rfa, gal, chl, bio, uvrB
- Species / strain / cell type:
- E. coli WP2 uvr A
- Details on mammalian cell type (if applicable):
- CELL SOURCES:
- Source of cells: Master culture from The National Collections of Industrial and Marine Bacteria, Aberdeen, UK - Additional strain / cell type characteristics:
- other: The Escherichia coli WP2uvrA strain detects base-pair substitutions
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix
- Test concentrations with justification for top dose:
- Selection of an adequate range of doses was based on a dose range finding test with the strains TA100 and WP2uvrA.
Strains TA100 and WP2uvrA: 3, 10, 33, 100, 333, 1000, 3330 and 5000 µg/plate
Strains TA1535, TA1537 and TA98: 100, 333, 1000, 3330 and 5000 µg/plate
The highest concentration of L(+)-lactic acid used in the subsequent mutation assay was 5000 μg/plate. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Milli-Q water
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Milli-Q water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- Remarks:
- without S9; WP2uvrA; 15 μg/plate; dissolved in DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Milli-Q water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- without S9; TA100; 650 μg/plate; dissolved in DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Milli-Q water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- Remarks:
- without S9; TA98; 10 μg/plate; dissolved in DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Millli-Q water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: ICR-191
- Remarks:
- without S9; TA1537; 2.5 μg/plate; dissolved in DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Milli-Q water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- without S9; TA1535; 5 μg/plate; dissolved in saline
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Milli-Q water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene
- Remarks:
- with S9; 1 µg/plate (TA98: 5 and 10% S9, TA100: 5% S9), 2 µg/plate (TA100: 10% S9), 2.5 µg/plate (TA1535: 5 and 10% S9; TA1537: 5% S9); dissolved in DMSO
- Details on test system and experimental conditions:
- Dose Range Finding Test:
Selection of an adequate range of doses was based on a dose range finding test with the strains TA100 and WP2uvrA, both with and without 5% (v/v) S9-mix. Eight concentrations, 3, 10, 33, 100, 333, 1000, 3330 and 5000 µg/plate were tested in triplicate. The highest concentartion of lactic aqcid used in the subsequent mutation assay was 5000 µg/plate.
Mutation Assay:
At least five different doses (increasing with approximately half-log steps) of the test substance were tested in triplcate in each strain. In the first experiment the test item was tested both in the absence and presence of 5% (v/v) S9-mix in tester strains TA1535, TA1537 and TA98. In an independent repeat of the assay with additional parameters, the test substance was tested both on the absence and presence of 10% (v/v) S9-mix in all tester strains. The negative control (vehicle) and relevant postive controls were concurrently tested in each strain in the presence and absence of S9-mix.
Top agar in top agar tubes was melted by heating to 45 °C. The following solutions were successively added to 3 mL molten top agar: 0.1 mL of a fresh bacterial culture (10^9 cells/mL) of one of the tester strains, 0.1 mL of a diltuin of the test substance in Milli-Q-water and either 0.5 mL S9-mix or 0.5 mL 0.1 M phosphate buffer. The ingredients were mixed on a Vortex and the content of the top agar tube was poured onto a selective agar plate. After solidification of the top agar, the plates were inverted and incubated in the dark at 37.0 °C +/- 1.0 °C for 48 +/- 4 hours. After this period revertant colonies were counted.
NUMBER OF REPLICATIONS: 3
Colony counting:
The revertant colonies were counted manually and evidenve of the test article precipitation on the plates was recorded.
DETERMINATION OF CYTOTOXICITY
- Method: The reduction of the bacterial background lawn was evaluated. - Evaluation criteria:
- A test substance is considered negative (not mutagenic) in the test if:
a) The total number of revertants in tester strain TA100 is not greater than two times the concurrent control, and the total number of revertants in tester strains TA1535, TA1537, TA98 or
WP2uvrA is not greater than three (3) times the concurrent vehicle control.
b) The negative response should be reproducible in at least one independently repeated experiment.
A test substance is considered positive (mutagenic) in the test if:
a) The total number of revertants in tester strain TA100 is greater than two times the concurrent control, or the total number of revertants in tester strains TA1535, TA1537, TA98 or WP2uvrA is greater than three times the concurrent vehicle control.
b) In case a repeat experiment is performed when a positive response is observed in one of the tester strains, the positive response should be reproducible in at least one independently repeated experiment.
The preceding criteria were not absolute and other modifying factors might enter into the final evaluation decision. - Statistics:
- not applicable
- Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: No
RANGE-FINDING/SCREENING STUDIES: Dose range finding test performed with TA100 and WP2uvrA. Doses tested: 0, 3, 10, 33, 100, 333, 1000, 3330, 5000 µg/plate. Based on the results, the following doses were selected for the main experiment with TA1535, TA1537 and TA98 in the presence and absence of S9-mix: 100, 333, 1000, 330 and 5000 µg/plate.
COMPARISON WITH HISTORICAL CONTROL DATA: The negative control values were within the laboratory historical control data ranges, except for TA100 in the absence of S9-mix, second experiment. Evaluation: The mean plate count (146) was just outside the limit of the range (144) and clear negative results are observed in all experiments. Therefore, this deviation in the mean plate count of the solvent control had no effect on the results of the study. The strain-specific positive control values were within the laboratory historical control data ranges indicating that the test conditions were adequate and that the metabolic activation system functioned properly, except the response for TA1535 in the absence of S9-mix, first experiment. Evaluation: The value (257) was just below the limit of the range (262). The purpose of the positive control is as a reference for the test system, where a positive response is required to check if the test system functions correctly. Since the value was more than 3 times greater than the concurrent solvent control values, this deviation in the mean plate count of the positive control had no effect on the results of the study.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
No reduction of the bacterial background lawn and no biologically relevant decrease in the number of revertants were observed.
MUTAGENICITY:
Experiment 1: No increase in the number of revertants was observed upon treatment with the test item under all conditions tested.
Experiment 2: Based on the results from the first experiment, the test item was tested up to 5000 µg/plate. No increase in the number of revertants was observed. - Conclusions:
- In conclusion, L(+)-lactic acid is not genotoxic in the bacterial reverse gene mutation assay (OECD 471) in the presence and absence of mammalian metabolic activation.
- Executive summary:
In a reverse gene mutation assay in bacteria conducted according to OECD guideline 471, Salmonella typhimurium strains TA1535, TA1537, TA98, TA100 and E. coli strain WP2uvrA were exposed to L(+)-lactic acid (90% purity) at concentrations of 0, 100, 333, 1000, 3330 and 5000 µg/plate in the presence and absence of mammalian metabolic activation.
L(+)-lactic acid was tested up to the limit concentration of 5000 µg/plate. The positive controls induced the appropriate responses in the corresponding strains. There was no evidence of induced mutant colonies over background. Based on the results, the test item can be considered to be non-mutagenic.
This study is classified as acceptable and satisfies the requirement for Test Guideline OECD 471 for in vitro mutagenicity (bacterial reverse gene mutation assay).
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2014-05-06 to 2014-08-26
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- adopted July 21, 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 490 (In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian cell gene mutation tests using the thymidine kinase gene
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): L(+)-lactic acid
- Analytical purity: 90%
- Lot/batch No.: 1208002033
- Physical state: clear, colourless liquid
- Expiration date of the lot/batch: 2015-01-01
- Stability under test conditions: valid expiry date
- Storage condition of test material: room temperature in the dark
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing:
The test substance was dissolved in RPMI 1640 (exposure medium, Hepes buffered medium (Dutch modification) (Invitrogen Corporation, Breda, The Netherlands). L(+)-lactic acid concentrations were used within 2 hours after preparation. - Target gene:
- thymidine kinase (TK)
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: American Type Culture Collection, (ATCC, Manassas, USA, 2001)
- Suitability of cells: L5178Y mouse lymphoma cells are used because they are sensitive indicators of mutagenic activity of a broad range of chemical classes.
CELL CULTURE
- Horse serum: Horse serum (Invitrogen Corporation) was inactivated by incubation at 56 °C for at least 30 minutes.
- Basic medium: RPMI 1640 Hepes buffered medium (Dutch modification) (Invitrogen Corporation) containing penicillin/streptomycin (50 U/mL and 50 μg/mL, respectively) (Invitrogen), 1 mM sodium pyruvate (Sigma) and 2 mM L-glutamin (Invitrogen Corporation).
- Growth medium: Basic medium, supplemented with 10% (v/v) heat-inactivated horse serum (=R10 medium).
- Selective medium: Selective medium consisted of basic medium supplemented with 20% (v/v) heat-inactivated horse serum (total amount of serum = 20%, R20) and 5 μg/mL trifluorothymidine (TFT) (Sigma).
- Non-selective medium: Non-selective medium consisted of basic medium supplemented with 20% (v/v) heat-inactivated horse serum (total amount of serum = 20%, R20). - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix
- Test concentrations with justification for top dose:
- 0.54, 1.7, 5.4, 17, 52, 164, 512, 901 µg/mL which is equal to concentrations of 0.006, 0.02, 0.06, 0.6, 1.8, 5.7 and 10 mM.
The highest dose of 901 µg/mL is a limit test concentration of 10 mM (= 0.01 M). A concentration of 0.01 M (901 μg/mL) L(+)-lactic acid showed no precipitation in the culture medium. Therefore, a concentration of 0.01 M was used as the highest concentration of L(+)-lactic acid. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: RPMI 1640
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- solvent: RPMI 1640
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- -S9, 15 and 5 µg/mL for 3 and 24 h treatment period
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- solvent: RPMI 1640
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- +S9, 7.5 µg/mL
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 3 hours in the first experiment (with and without metabolic activation), 24 hours in the second experiment (without metabolic activation)
- Expression time (cells in growth medium): 2 days
- Selection time (if incubation with a selection agent): 11 or 12 days
SELECTION AGENT (mutation assays): 5 µg/mL trifluorothymidine
STAIN (for cytogenetic assays): 0.5 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
DETERMINATION OF CYTOTOXICITY
- Method: For determination of the cytotoxicity, the surviving cells of the 3 hours treatment were subcultured twice. After 24 hours of subculturing, the cells were counted (day 1) and subcultured again for another 24 hours, after which the cells were counted (day 2). The surviving cells of the 24 hours treatment were su cultured once. After 24 hours of subculturing, the cells were counted. If less than 1.25 x 10^5 cells/mL were counted no subculture was performed. - Evaluation criteria:
- A test substance is considered positive (mutagenic) in the mutation assay if it induces a MF of more than MF(controls) + 126 in a dose-dependent manner. An observed increase should be biologically relevant and will be compared with the historical control data range.
A test substance is considered equivocal (questionable) in the mutation assay if no clear conclusion for positive or negative result can be made after an additional confirmation study.
A test substance is considered negative (not mutagenic) in the mutation assay if:
a) None of the tested concentrations reaches a mutation frequency of MF(controls) + 126.
b) The results are confirmed in an independently repeated test. - Statistics:
- The mutation frequency was expressed as the number of mutants per 10^6 viable cells. The plating efficiencies of both mutant and viable cells (CE day 2) in the same culture were determined and the mutation frequency (MF) was calculated as follows:
MF = {-ln P(0)/number of cells plated per well}/ CE day2 x 10^6
Small and large colony mutation frequencies were calculated in an identical manner. - Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: At the highest concentration of test substance (0.01 M equal to 901 µg/mL) the pH was 6.84 compared to a pH of 7.31 in the solvent control.
- Effects of osmolality: At the highest concentration of test substance (0.01 M equal to 901 µg/mL) the osmolarity was 0.319 Osm/kg compared to an osmolarity of 0.299 Osm/kg in the solvent control
- Water solubility: miscible
- Precipitation: No
RANGE-FINDING/SCREENING STUDIES:
Cytotoxicity data were obtained by treating 8 x 10^6 cells (10^6 cells/mL for 3 hours treatment) or 5 x 10^6 cells (1.25 x 10^5 cells/mL for 24 hours treatment) with 0, 17, 52, 164, 512 and 901 µg of test substance for 3 hours in the presence of S9-mix and for 3 and 24 hours in the absence of S9-mix.
After exposure, the cells were separated from treatment solutions centrifugation steps and re-suspended in RPM 1640 medium supplemented with 10% (v/v) inactivated horse serum (R10 medium). Cells were counted with the coulter particle counter.
For determination of the cytotoxicity, the surviving cells of the 3 hours treatment were subcultured twice. After 24 hours of subculturing, the cells were counted (day 1) and subcultured again for another 24 hours, after which the cells were counted (day 2). The surviving cells of the 24 hours treatment were subcultured once. After 24 hours of subculturing, the cells were counted. If less than 1.25 x 105 cells/mL were counted no subculture was performed.
The suspension growth expressed as the reduction in cell growth after approximately 24 and 48 hours or only 24 hours cell growth, compared to the cell growth of the solvent control, was used to determine an appropriate dose range for the mutagenicity tests.
COMPARISON WITH HISTORICAL CONTROL DATA:
Spontaneous mutation frequencies in the solvent-treated control cultures were between the minimum and maximum value of the historical control range.
Experiment 1 & 2: For individual results see Tables 3-5 in box 'Any other information on results incl. tables'. - Conclusions:
- In conclusion, L(+)-lactic acid is considered to be non-mutagenic in the in vitro mammalian cell gene mutation test (OECD 476, nowadays OECD 490) in the presence and absence of mammalian metabolic activation.
- Executive summary:
In a mammalian cell gene mutation assay conducted in accordance to OECD guideline 476 (nowadays OECD 490), L5178Y mouse lymphoma cells cultured in vitro were exposed to L(+)-lactic acid (90% purity), solved in RPMI 1640 medium. In the first experiment, L(+)-lactic acid was tested up to concentrations of 901 µg/mL (0.01 M, the highest concentration recommended in the guidelines) in the absence and presence of S9-mix. The incubation time was 3 hours. In the second experiment, L(+)-lactic acid was again tested up to concentrations of 901 µg/mL in the absence S9-mix. The incubation time was 24 hours. No toxicity was observed at this dose level in the absence and presence of S9 mix. The induced mutation frequency with and without metabolic activation was not increased compared to control in all tested concentrations. The positive controls did induce the appropriate response. Based on the results, it can be concluded, that L(+)-lactic acid is not mutagenic in the mouse lymphoma L5178Y test system under the experimental conditions described.
Referenceopen allclose all
Mitotic Indices:
Table 1: Mitotic index of human lymphocyte cultures treated with L(+)-lactic acid in the dose range finding test
L(+)-lactic acid concentration (µg/mL) |
Number of metaphases:
Absolute |
Number of metaphases:
Number of cells scored |
Number of metaphases:
Percentage of control |
Without metabolic activation (-S9-mix) |
|
|
|
3 h exposure time, 24 h fixation time |
|
|
|
Control a) |
96 |
1004 |
100 |
10 |
99 |
1007 |
103 |
33 |
80 |
1045 |
83 |
100 |
60 |
1008 |
63 |
333 |
66 |
1009 |
69 |
901 |
63 |
1003 |
66 |
24 h exposure time, 24 h fixation time |
|
|
|
Control a) |
65 |
1007 |
100 |
10 |
62 |
1042 |
95 |
33 |
71 |
1041 |
109 |
100 |
66 |
1016 |
102 |
333 |
68 |
1048 |
105 |
901 |
36 |
1028 |
55 |
48 h exposure time, 48 h fixation time |
|
|
|
Control a) |
68 |
1017 |
100 |
10 |
64 |
1026 |
94 |
33 |
51 |
1013 |
75 |
100 |
65 |
1010 |
96 |
333 |
57 |
1017 |
84 |
901 |
33 |
1033 |
49 |
With metabolic activation (+S9-mix) |
|
|
|
3 h exposure time, 24 h fixation time |
|
|
|
Control a) |
85 |
1044 |
100 |
10 |
70 |
1013 |
82 |
33 |
71 |
1008 |
84 |
100 |
68 |
1006 |
80 |
333 |
66 |
1020 |
78 |
901 |
71 |
1007 |
84 |
a) culture medium
Table 2: Mitotic index of human lymphocyte cultures treated with L(+)-lactic acid in the first cytegenetic assay
lactic acid concentration (µg/mL) |
Number of metaphases a)
Absolute |
Number of metaphases a)
Number of cells scored |
Percentage of control
|
Without metabolic activation (-S9-mix) |
|
|
|
3 h exposure time, 24 h fixation time |
|
|
|
Control b) |
34-36 |
1009-1028 |
100 |
10 |
37-35 |
1002-1012 |
103 |
100 |
35-28 |
1008-1033 |
90 |
901 |
15-9 |
1002-1040 |
34 |
MMC-C; 0.5 µg/mL |
4-7 |
1026-1031 |
16 |
MMC-C; 0.75 µg/mL |
7-5 |
1029-1004 |
17 |
With metabolic activation (+S9-mix) |
|
|
|
3 h exposure time, 24 h fixation time |
|
|
|
Control b) |
33-48 |
1040-1028 |
100 |
10 |
37-27 |
1013-1007 |
79 |
100 |
47-35 |
1035-1001 |
101 |
901 |
43-32 |
1008-1007 |
93 |
CP; 10 µg/ml |
21-14 |
1005-1025 |
43 |
a) Duplicate cultures
b) Culture medium
Table 3: Mitotic index of human lymphocyte cultures treated with L(+)-lactic acid in the second cytogenetic assay
L(+)-lactic acid concentration (µg/mL) |
Number of metaphases a)
Absolute |
Number of metaphases a)
Number of cells scored |
Percentage of control |
Without metabolic activation (-S9-mix) |
|
|
|
24 h exposure time, 24 h fixation time |
|
|
|
Control b) |
90-85 |
1000-1000 |
100 |
100 |
75-83 |
1000-1003 |
90 |
333 |
67-65 |
1008-1000 |
75 |
666 |
73-66 |
1001-1000 |
79 |
901 |
39-42 |
1002-1000 |
46 |
MMC-C; 0.2 µg/mL |
24-34 |
1000-1003 |
33 |
MMC-C; 0.3 µg/mL |
21-33 |
1003-1000 |
31 |
48 h exposure time, 48 h fixation time |
|
|
|
Control b) |
93-88 |
1005-1000 |
100 |
100 |
71-87 |
1001-1000 |
87 |
333 |
66-51 |
1000-1000 |
65 |
666 |
34-37 |
1000-1002 |
39 |
901 |
22-24 |
1003-1000 |
25 |
MMC-C; 0.1 µg/mL |
18-20 |
1002-1003 |
21 |
MMC-C; 0.15 µg/mL |
17-19 |
1000-1004 |
20 |
With metabolic activation (+S9-mix) |
|
|
|
3 h exposure time, 48 h fixation time |
|
|
|
Control b) |
88-87 |
1000-1000 |
100 |
10 |
66-75 |
1000-1045 |
81 |
100 |
62-64 |
1003-1005 |
72 |
901 |
71-63 |
1000-1000 |
77 |
CP; 10 µg/mL |
22-18 |
1005-1000 |
- c) |
a) Duplicate cultures
b) Culture medium
c) CP was fixed after 24 hours. Therefore, the mitotic index could not be calculated as percentage of control.
Chromosome aberrations in human lymphocyte cultures treated with L(+)-lactic acid
1. Cytogenetic Assay:
Conc | Exposure Time [h] | Fixation Time [h] | Metabolic Activation | Culture | Mitotic Index [%] | Cells scored |
Cells + gaps |
Cells - gaps |
Culture medium | 3 | 24 | without | A+B | 100 | 200 | 0 | 0 |
10 µg/ml | 3 | 24 | without | A+B | 103 | 200 | 5 | 5 |
100 µg/ml | 3 | 24 | without | A+B | 90 | 200 | 0 | 0 |
901 µg/ml | 3 | 24 | without | A+B | 34 | 200 | 4 | 4 |
MMC-C 0.5 µg/ml | 3 | 24 | without | A+B | 16 | 150 | 76*** | 76*** |
Culture medium | 3 | 24 | with | A+B | 100 | 200 | 2 | 2 |
10 µg/ml | 3 | 24 | with | A+B | 79 | 200 | 3 | 3 |
100 µg/ml | 3 | 24 | with | A+B | 101 | 200 | 2 | 2 |
901 µg/ml | 3 | 24 | with | A+B | 93 | 200 | 2 | 2 |
CP 10 µg/ml | 3 | 24 | with | A+B | 43 | 200 | 59*** | 59*** |
*) Significantly different from control group (Chi-square test), p < 0.001
2. Cytogenetic Assay:
Conc | ExposureTime [h] | FixationTime [h] | Metaboic Activation | Culture | Mitotic Index [%] |
Cells scored |
Cells + gaps |
Cells - gaps |
Culture medium | 3 | 48 | with | A+B | 100 | 200 | 2 | 1 |
10 µg/ml | 3 | 48 | with | A+B | 81 | 200 | 1 | 1 |
100 µg/ml | 3 | 48 | with | A+B | 72 | 200 | 0 | 0 |
10 µg/ml | 3 | 48 | with | A+B | 77 | 200 | 3 | 3 |
CP 10 µg/ml | 3 | 48 | with | A+B | n.d.b | 100 | 53*** | 53*** |
Culture medium | 24 | 24 | without | A+B | 100 | 200 | 1 | 1 |
100 µg/ml | 24 | 24 | without | A+B | 90 | 200 | 1 | 1 |
666 µg/ml | 24 | 24 | without | A+B | 79 | 200 | 0 | 0 |
901 µg/ml | 24 | 24 | without | A+B | 46 | 200 | 3 | 3 |
MMC- 0.1 µg/ml | 24 | 24 | without | A+B | 33 | 100 | 53*** | 53*** |
Culture medium | 48 | 48 | without | A+B | 100 | 200 | 1 | 1 |
100 µg/ml | 48 | 48 | without | A+B | 87 | 200 | 3 | 3 |
333 µg/ml | 48 | 48 | without | A+B | 65 | 200 | 2 | 2 |
666 µg/ml | 48 | 48 | without | A+B | 39 | 200 | 2 | 2 |
MMC- 0.1 µg/ml | 48 | 48 | without | A+B | 21 | 100 | 53*** | 53*** |
bCP was fixed after 24 hours. Therefore, the mitotic index could not be calculated as percentage of control.
*) Significantly different from control group (Chi-square test), p < 0.001
Table 1: Dose-range finding test: Cytotoxicity of L(+)-lactic acid (3 hours treatment)
Dose (µg/mL) |
Cell count after 3 hours of treatment (cells/mL x 10^5) | Cell count after 24 hours of subculture (cells/mL x 10^5) | Cell count after 48 hours of subculture (cells/mL x 10^5) | SG(1) x 10^5 cells/mL) |
RSG (2) % |
without metabolic activation |
|||||
SC | 6.9 | 5.0 | 6.9 | 152 | 100 |
17 | 6.3 | 5.0 | 7.4 | 149 | 98 |
52 | 7.0 | 5.2 | 6.9 | 161 | 106 |
164 | 7.3 | 5.2 | 7.1 | 173 | 113 |
512 | 7.6 | 5.2 | 6.8 | 172 | 113 |
901 | 6.8 | 5.4 | 7.0 | 166 | 109 |
with metabolic activation |
|||||
SC | 5.3 | 4.9 | 7.8 | 130 | 100 |
17 | 5.2 | 5.2 | 7.5 | 130 | 100 |
52 | 4.2 | 5.2 | 7.6 | 106 | 82 |
164 | 4.1 | 5.3 | 7.2 | 100 | 77 |
512 | 5.0 | 5.1 | 7.5 | 122 | 94 |
901 | 4.3 | 5.1 | 7.4 | 104 | 80 |
Note: all calculations were made without rounding off
SC = solvent control = exposure medium
(1) = suspension growth
(2) relative suspension growth
SG= (Cell count after 3 h treatment) x (Cell count after 24 h subculture)/(Cells subcultured (at t=3 h)(1.25x10^5 c/mL)) x (Cell count after 48 h subculture)/(Cells subcultured (at t=24 h) (1.25 x 10^5 c/mL))
RSG = [SG(test)/SG(control)] x 100
Table 2: Dose-range finding test: Cytotoxicity of L(+)-lactic acid (24 hours treatment)
Dose (µg/mL) |
Cell count after 24 hours of treatment (cells/mL x 10^5) | Cell count after 24 hours of subculture (cells/mL x 10^5) | SG(1) x 10^5 cells/mL) |
RSG (2) % |
without metabolic activation |
||||
SC |
9.5 | 5.9 | 45 | 100 |
17 | 8.9 | 5.9 | 42 | 93 |
52 | 9.3 | 5.7 | 42 | 93 |
164 | 9.1 | 5.2 | 39 | 85 |
512 | 8.8 | 5.5 | 39 | 87 |
901 | 7.2 | 4.6 | 26 | 58 |
Note: all calculations were made without rounding off
SC = solvent control = exposure medium
(1) = suspension growth
(2) relative suspension growth
SG = (Cell count after 24 h treatment) x (Cell count after 24 h subculture)/(Cells subcultured after treatment (1.25 x 10^5 c/mL)
RSG = [SG(test)/SG(control)] x 100
Cytotoxic and mutagenic response of L(+)-lactic acid in the mouse lymphoma L5178Y test system
Abbreviations:
RSG: Relative Suspension Growth
CE: Cloning Efficiency
RS: Relative Survival
RTG: Relative Total Growth
MF: Mutation Frequency per 10^6 Survivors
SC: Solvent Control (= Exposure Medium)
MMS: Methylmethanesulfonate
CP: Cyclophosphamide
Experiment 1
Table 3: 3 h treatment, without metabolic activation
Dose [µg/mL] |
RSG [%] |
CEday2 [%] |
RSday2 [%] |
RTG [%] |
MF total |
MF small |
MS large |
SC1 | 100 | 97 | 100 | 100 | 89 | 70 | 16 |
SC2 | 100 | 80 | 100 | 100 | 86 | 66 | 18 |
0.54 | 107 | 86 | 98 | 105 | 98 | 71 | 25 |
1.7 | 118 | 79 | 89 | 106 | 98 | 72 | 23 |
5.4 | 126 | 83 | 93 | 117 | 94 | 62 | 28 |
17 | 129 | 77 | 87 | 112 | 122 | 91 | 26 |
52 | 108 | 75 | 84 | 91 | 124 | 97 | 23 |
164 | 112 | 78 | 88 | 99 | 104 | 66 | 34 |
512 | 106 | 72 | 82 | 87 | 147 | 99 | 41 |
901 | 101 | 88 | 99 | 100 | 116 | 89 | 23 |
MMS | 79 | 41 | 47 | 37 | 1149 | 870 | 191 |
Table 4: 3 h treatment, with metabolic activation
Dose [µg/mL] |
RSG [%] |
CEday2 [%] |
RSday2 [%] |
RTG [%] |
MF total |
MF small |
MS large |
SC1 | 100 | 68 | 100 | 100 | 51 | 26 | 23 |
SC2 | 100 | 64 | 100 | 100 | 55 | 30 | 25 |
0.54 | 92 | 78 | 118 | 108 | 53 | 31 | 20 |
1.7 | 78 | 111 | 168 | 132 | 26 | 17 | 8 |
5.4 | 56 | 93 | 140 | 79 | 38 | 28 | 10 |
17 | 60 | 97 | 146 | 88 | 31 | 22 | 9 |
52 | 65 | 66 | 100 | 65 | 62 | 47 | 14 |
164 | 92 | 74 | 111 | 102 | 53 | 45 | 7 |
512 | 64 | 77 | 116 | 74 | 45 | 12 | 32 |
901 | 93 | 81 | 123 | 114 | 45 | 25 | 19 |
CP | 37 | 29 | 43 | 16 | 849 | 647 | 167 |
Experiment 2
Table 5: 24 h treatment, without metabolic activation
Dose [µg/mL] |
RSG [%] |
CEday2 [%] |
RSday2 [%] |
RTG [%] |
MF total |
MF small |
MS large |
SC1 | 100 | 98 | 100 | 100 | 57 | 26 | 30 |
SC2 | 100 | 102 | 100 | 100 | 50 | 19 | 30 |
0.54 | 92 | 84 | 84 | 77 | 63 | 19 | 42 |
1.7 | 91 | 86 | 86 | 78 | 71 | 40 | 28 |
5.4 | 99 | 89 | 89 | 88 | 65 | 25 | 38 |
17 | 90 | 89 | 89 | 80 | 49 | 11 | 38 |
52 | 86 | 98 | 98 | 84 | 51 | 16 | 34 |
164 | 85 | 88 | 87 | 74 | 72 | 34 | 36 |
512 | 78 | 90 | 90 | 71 | 50 | 22 | 26 |
901 | 64 | 107 | 107 | 68 | 53 | 9 | 43 |
MMS | 80 | 61 | 61 | 49 | 621 | 198 | 368 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
L(+)-lactic acid was tested in an in vitro test battery, which were performed in accordance with the OECD guidelines 471 (Ames test), 473 (chromosome aberration) and 476 (MLA, nowadays OECD 490).
In the bacterial reverse mutation test four strains of Salmonella typhimurium, TA1535, TA1537, TA100 and TA98 plus the Escherichia coli strain WP2uvrA were treated with L(+)-lactic acid up to the limit concentration of 5000 µg/plate. No precipitation occurred and the bacterial growth was undisturbed, indicative of the non-cytotoxicity of L(+)-lactic acid. No increase in the rate of revertant colonies was observed in all of the triplicates tested for each concentration (0, 100, 333, 1000, 3330 and 5000 µg/plate) with and without addition of S9-mix. The positive controls induced the appropriate response; the negative controls laid within the historical background. Thus, L(+)-lactic acid was not mutagenic in the bacterial reverse mutation assay.
Two further in vitro test were performed in mammalian cells. A gene mutation assay used L5178Y mouse lymphoma cells was conducted to study the impact of L(+)-lactic acid on the rate of forward mutation at the thymidine-kinase locus. The test was conducted in the presence and absence of metabolic activation with exposure times of 3 hours (with and without) and 24 hours (without). L(+)-lactic acid failed to be cytotoxic in a dose-dependent manner, reducing the cloning efficiency, given as percent, to roughly 84 percent. The highest test concentration was chosen in accordance to the proposed limit test concentration of OECD guideline 476, which is 0.01 M and corresponded to a dose of 901 µg/mL L(+)-lactic acid. 8 doses between 0.54 and 901 µg/mL L(+)-lactic acid were tested, not resulting in an increase of mutation frequency per 10^6 survivors in the presence or absence of metabolic activation with 3 or 24 hours exposure time. The positive controls induced the appropriate response and negative controls were in the historical control range. Thus, L(+)-lactic acid is considered as not mutagenic.
The third in vitro test was a chromosome aberration test in cultured peripheral human lymphocytes. Five doses of L(+)-lactic acid were tested ranging from 10 to 901 µg/mL. For cytotoxicity assessment, the mitotic index was determined. 2 experiments were conducted; the first one used 3 hours exposure time, followed by a fixation time of 24 hours in the presence and absence of metabolic activation. The second experiment exposed peripheral human lymphocytes for 24 and 48 hours to L(+)-lactic acid followed by equal fixation time (24 and 48 hours, respectively) and in a third conditions with metabolic activation exposed the cells for 3 hours, followed by a 48 hours fixation time. Upon 3 hours of exposure the mitotic index, given as percent, was reduced to 34 percent in the absence of metabolic activation, but only 93 and 77 percent with metabolic activation in the highest concentration of 901 µg/ml. Upon 24 and 48 hours exposure time, the mitotic indices were 46 percent (24 h, 901 µg/mL) and 39 percent (48 hours, 666 µg/mL). Thus, the reduction of the mitotic indices were significant at a dose of 901 (or 666) µg/mL. It has to be mentioned, that the mitotic index gives rather an estimate about the rate of the cells undergoing proliferation then the actual percentage of dead cells. With this, the difference in assessment of cytotoxicity between the gene mutation test (where no cytotoxicity has been observed) and the lowered rate of mitotic indices in the chromosome aberration test is not conflicting.
After the fixation time, cells with chromosome aberrations were counted, resulting in no significant increase over control levels for all exposure and fixation times tested in the presence and absence of metabolic activation. The positive controls induced the appropriate response and the negative controls were within the historical background range.
In addition to these three guideline studies with the target substance, four publications and one review article report further results on the genotoxic potential of lactic acid. No positive results were reported, with exception of Morita (1990), where some chromosome aberrations had been found under non-physiological conditions, i.e. low pH. The same study reports negative findings under physiological conditions, whereas the positive finding is of no toxicological relevance. The review article by Andersen (1998) displays the findings of 11 studies, which were all negative. Therefore, in view of all genotoxicity tests, L(+)-lactic acid is considered as not genotoxic.
Justification for classification or non-classification
Based on the available results, the target substance L(+) lactic acid is not considered to be genotoxic and no classification is warranted in accordance with CLP Regulation 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.